Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat.
Alzheimer's disease
BACE-1
amyloid beta
amyloid plaques
synapse
verubecestat
Journal
Neuropathology and applied neurobiology
ISSN: 1365-2990
Titre abrégé: Neuropathol Appl Neurobiol
Pays: England
ID NLM: 7609829
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
16
09
2021
received:
15
06
2021
accepted:
13
11
2021
pubmed:
27
11
2021
medline:
7
4
2022
entrez:
26
11
2021
Statut:
ppublish
Résumé
We report the neuropathological examination of a patient with Alzheimer's disease (AD) treated for 38 months with low doses of the BACE-1 inhibitor verubecestat. Brain examination showed small plaque size, reduced dystrophic neurites around plaques and reduced synaptic-associated Aβ compared with a group of age-matched untreated sporadic AD (SAD) cases. Our findings suggest that BACE-1 inhibition has an impact on synaptic soluble Aβ accumulation and neuritic derangement in AD.
Substances chimiques
Amyloid beta-Peptides
0
Cyclic S-Oxides
0
Thiadiazines
0
verubecestat
J1I0P6WT7T
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12781Informations de copyright
© 2021 British Neuropathological Society.
Références
Das B, Yan R. A close look at BACE1 inhibitors for Alzheimer's disease treatment. CNS Drugs [Internet]. 2019;33(3):251-263. https://doi.org/10.1007/s40263-019-00613-7
Scott JD, Li SW, Brunskill APJ, et al. Discovery of the 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative verubecestat (MK-8931)-a β-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer's disease. J Med Chem. 2016;59(23):10435-10450.
Lovestone S, Boada M, Dubois B, et al. A phase II trial of tideglusib in Alzheimer's disease. J Alzheimers Dis. 2015;45(1):75-88.
Egan MF, Kost J, Tariot PN, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease. N Engl J Med. 2018;378(18):1691-1703.
Lee EB, Leng LZ, Zhang B, et al. Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J Biol Chem. 2006;281(7):4292-4299.
Monsell SE, Kukull WA, Roher AE, et al. Characterizing apolipoprotein E ε4 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal β-amyloid peptide plaques. JAMA Neurol. 2015;72(10):1124-1131.
Gomez-Arboledas A, Davila JC, Sanchez-Mejias E, et al. Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease. Glia. 2018;66(3):637-653.
Hadley KC, Rakhit R, Guo H, et al. Determining composition of micron-scale protein deposits in neurodegenerative disease by spatially targeted optical microproteomics. Elife. 2015;4:1-21.
Sadleir KR, Kandalepas PC, Buggia-Prévot V, Nicholson DA, Thinakaran G, Vassar R. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease. Acta Neuropathol. 2016;132(2):235-256.
Egan MF, Kost J, Voss T, et al. Randomized trial of verubecestat for prodromal Alzheimer's disease. N Engl J Med. 2019;380(15):1408-1420.
Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Romano G. Preliminary results of a trial of atabecestat in preclinical Alzheimer's disease. N Engl J Med. 2019;380(15):1483-1485.
Peters F, Salihoglu H, Rodrigues E, et al. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology. Acta Neuropathol [Internet]. 2018;135(5):695-710. https://doi.org/10.1007/s00401-017-1804-9
Das B, Yan R. Role of BACE1 in Alzheimer's synaptic function. Transl Neurodegener. 2017;6(1):4-11.
Selkoe DJ. Alzheimer's disease is a synaptic failure. Science (80-). 2002;298(5594):789-791.
Kandalepaas PC, Sadleir KR, Eimer WA, Zhao J, Nicholson DA, Vassar R. The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol. 2013;126(3):329-352.